Cohance Lifesciences Limited (BOM:543064)

India flag India · Delayed Price · Currency is INR
308.75
+0.60 (0.19%)
At close: Feb 27, 2026
-74.46%
Market Cap 118.58B
Revenue (ttm) 10.79B
Net Income (ttm) 606.40M
Shares Out n/a
EPS (ttm) 2.35
PE Ratio 195.54
Forward PE 33.04
Dividend n/a
Ex-Dividend Date n/a
Volume 26,599
Average Volume 176,079
Open 307.75
Previous Close 308.15
Day's Range 303.10 - 314.10
52-Week Range 303.10 - 1,246.85
Beta n/a
RSI 28.99
Earnings Date Feb 12, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores... [Read more]

Industry Pharmaceutical Preparations
Founded 1989
Employees 1,212
Stock Exchange Bombay Stock Exchange
Ticker Symbol 543064
Full Company Profile

Financial Performance

In fiscal year 2025, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.

Financial Statements

News

There is no news available yet.